Vor Biopharma Inc (VOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vor Biopharma Inc (VOR) has a cash flow conversion efficiency ratio of 0.254x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.25 Million) by net assets ($-150.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VOR defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Vor Biopharma Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vor Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vor Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Frontera Energy Corp
TO:FEC
|
0.129x |
|
CECEP Guozhen Environmental Protection Technology Co Ltd
SHE:300388
|
0.032x |
|
Investment AB Oresund
ST:ORES
|
0.005x |
|
Goldcard High-Tech Co Ltd
SHE:300349
|
0.047x |
|
Guangzhou Jinzhong Auto Parts Manufacturing Co. Ltd.
SHE:301133
|
-0.041x |
|
Beijing ConST Instruments Technology Inc
SHE:300445
|
0.040x |
|
Nusantara Sawit Sejahtera
JK:NSSS
|
0.079x |
|
Norva24 Group AB
ST:NORVA
|
0.130x |
Annual Cash Flow Conversion Efficiency for Vor Biopharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vor Biopharma Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Vor Biopharma Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-164.31 Million | $-142.71 Million | 0.869x | +184.24% |
| 2024-12-31 | $96.66 Million | $-99.66 Million | -1.031x | -54.94% |
| 2023-12-31 | $150.72 Million | $-100.29 Million | -0.665x | -95.85% |
| 2022-12-31 | $250.61 Million | $-85.14 Million | -0.340x | -6.26% |
| 2021-12-31 | $216.26 Million | $-69.14 Million | -0.320x | +57.47% |
| 2020-12-31 | $48.27 Million | $-36.29 Million | -0.752x | +41.71% |
| 2019-12-31 | $7.64 Million | $-9.86 Million | -1.290x | -428.03% |
| 2018-12-31 | $-6.77 Million | $-2.66 Million | 0.393x | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more